Boston, MA 06/25/2013 (wallstreetpr) – The share prices of Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) had decreased by 8.83 percent to close at $7.54 per share on Monday. The range of trading is between $7.51 and $8.19 per share during the day, with an opening price of $8.16 per share. The shares of NIHD had a same 52 week low price level of $2.92 per share and the 52 week high price level of the company is at $13.30 per share.
Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) is a biopharmaceutical company noted for the commercialization and develops of products for various central nervous system disorders. The Company’s products known as Fanapt a compound for the treatment of schizophrenia and for the treatment of sleep and mood disorders a compound called Tasimelteon is used which includes Circadian Rhythm Sleep Disorders. For the treatment of schizophrenia the compound Fanapt is used.
An investigation on behalf of investors of Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) shares over potential securities laws violations by Vanda Pharmaceuticals Inc. and officers and certain directors in connection have announced the certain financial statements. Investors have their own option to purchased shares of Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA). The investigation focused on possible claims by a law firm on role of purchasers of the securities of Vanda Pharmaceuticals Inc, regarding its business whether a statement in series by Vanda Pharmaceuticals, its operations and prospectus were materially misleading and false at the time of they done. The company showed that it’s the Net Loss increased from $9.80 million to $27.66 million and annual Total Revenue rose from $31.27 million in 2011 to $32.73 million in 2012.
The shares of Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) had a volume with nearly 1.59 million trades on Monday having an average volume of 1.70 million shares per day. The company presently holds a share outstanding as 28.35 million in the market and the institutional ownership holding is about 72 percent.
